Influenza A virus subtype H7N9

Quantabio’s UltraPlex 1-Step ToughMix Continues to Enhance CDC Protocols to Detect and Differentiate COVID-19 and Influenza Respiratory Diseases

Retrieved on: 
Thursday, July 16, 2020
Science, Biotechnology, Research, Health, Infectious diseases, Technology, Genetics, Other Technology, Branches of biology, Natural sciences, Laboratory techniques, Molecular biology, Articles, RTT, Animal virology, Influenza A virus subtype H7N9, Avian influenza, Polymerase chain reaction, Real-time polymerase chain reaction, Influenza

The Flu SC2 Multiplex Assay protocol is the latest in a series of CDC EUA protocols to recommend Quantabio reagents for respiratory disease detection and differentiation.

Key Points: 
  • The Flu SC2 Multiplex Assay protocol is the latest in a series of CDC EUA protocols to recommend Quantabio reagents for respiratory disease detection and differentiation.
  • Since 2013, Quantabio products have been cited in testing protocols for H7N9 Avian Influenza , Polio and COVID-19 .
  • Quantabio is committed to supporting the adoption of the use of the UltraPlex 1-Step ToughMix in the CDC protocol by the stakeholders within the relevant government agencies.
  • UltraPlex 1-Step ToughMix is a ready-to-use, one-step, 4X concentrated RT-qPCR master mix 1-step that uses probe-based detection methods.

The 2020-2024 Chinese COVID-19 Pandemic Mitigation Products Market* Worth More than $188 Billion

Retrieved on: 
Monday, June 29, 2020
Articles, Coronaviridae, Animal virology, Influenza A virus subtype H7N9, Coronavirus, Pandemic, Virus, Health

Furthermore, according to the upcomingJuly 1, 2020updated report version, the cumulative 2020-2024 Global Coronavirus Pandemic Mitigation Products Market * is forecast to be worth between$1.6and$2.1 Trillion.

Key Points: 
  • Furthermore, according to the upcomingJuly 1, 2020updated report version, the cumulative 2020-2024 Global Coronavirus Pandemic Mitigation Products Market * is forecast to be worth between$1.6and$2.1 Trillion.
  • However, the crisis has had a dramatic and lingering impact on the Chinese economy.
  • During the 2013 H7N9 outbreak in East China, the country's health system identified the pathogen five days after the outbreak.
  • Besides, Chinese academic community was the first to reveal the virus's transmission methods, molecular mechanisms and effective treatment.

Moderna Announces Progress in Prophylactic Vaccines Modality with CMV Vaccine Phase 2 Study Data Now Expected in Third Quarter 2020 and Expands Investment in This Core Modality with Three New Development Candidates

Retrieved on: 
Monday, February 10, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Vaccines, Vaccination, Cytomegalovirus vaccine, Moderna, Vaccine, Medical specialties, Influenza A virus subtype H7N9, Medicine, Health, Moderna’s New Development Candidates, Epstein-Barr Virus (EBV), Respiratory Syncytial Virus (RSV), Coronavirus (2019-nCoV), Moderna’s Prophylactic Vaccines Modality, Moderna

Clinical data demonstrate that Modernas proprietary vaccine technology has been generally well-tolerated1 and can elicit durable immune responses to viral antigens.

Key Points: 
  • Clinical data demonstrate that Modernas proprietary vaccine technology has been generally well-tolerated1 and can elicit durable immune responses to viral antigens.
  • I am pleased with the continued progress of our late-stage CMV vaccine program as we prepare for a pivotal Phase 3 study and commercial readiness.
  • The three new development candidates reflect the continued productivity of our platform and the potential of our mRNA technology.
  • Moderna currently has nine development candidates in its prophylactic vaccines modality, including:
    To date, Moderna has demonstrated positive Phase 1 data readouts for six prophylactic vaccines (H10N8, H7N9, RSV, chikungunya virus, hMPV/PIV3 and CMV).

Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study

Retrieved on: 
Thursday, January 9, 2020
Health, Infectious diseases, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Medicine, Health, Moderna, Influenza A virus subtype H7N9, Chikungunya, Vaccine, Dose, the Planned Phase 3 Study, mRNA-1647, Cytomegalovirus (CMV), Moderna’s Prophylactic Vaccines Modality, Moderna

Additionally, the Company announced that the first participant was dosed in the Phase 2 dose-confirmation study.

Key Points: 
  • Additionally, the Company announced that the first participant was dosed in the Phase 2 dose-confirmation study.
  • mRNA-1647 is the first mRNA vaccine for an infectious disease to enter a Phase 2 clinical trial, said Stphane Bancel, Modernas chief executive officer.
  • This Phase 2 study will test the intended Phase 3 formulation, which contains the same proprietary lipid nanoparticle (LNP) used in the Phase 1 study.
  • To date, Moderna has demonstrated positive Phase 1 data readouts for six prophylactic vaccines (H10N8, H7N9, RSV, chikungunya virus, hMPV+PIV3 and CMV).

Moderna to Present Data From Two of Its Prophylactic mRNA Vaccines at IDWeek 2019

Retrieved on: 
Wednesday, October 2, 2019
Biotechnology, Pharmaceutical, Health, Infectious diseases, Genetics, Clinical trials, Life sciences, Branches of biology, Biotechnology, Moderna, RNA, Molecular genetics, Messenger RNA, Vaccine, Influenza A virus subtype H7N9, Moderna’s Development Candidates, Moderna’s Prophylactic Vaccines Modality, Moderna

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced data presentations regarding two of its wholly owned prophylactic mRNA vaccines at IDWeek in Washington, D.C.

Key Points: 
  • Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced data presentations regarding two of its wholly owned prophylactic mRNA vaccines at IDWeek in Washington, D.C.
  • The study is one of the six positive Phase 1 readouts Moderna has announced from its prophylactic vaccines portfolio to date.
  • We look forward to sharing Phase 1 data when available and continuing our work to improve public health through the development of mRNA vaccines.
  • To date, Moderna has demonstrated positive Phase 1 data readouts for six prophylactic vaccines (H10N8, H7N9, RSV [mRNA-1777], chikungunya virus, hMPV+PIV3 and CMV).